Novonesis Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ester Baiget

Chief Executive Officer (CEO)

€3.9m

Compensación total

Porcentaje del salario del CEO	33.3%
Permanencia del CEO	4.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ester Baiget en comparación con los beneficios de Novonesis?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Compensación vs. Mercado: La compensación total ($USD4.11M) de Ester está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD4.83M).

Compensación vs. Ingresos: La compensación de Ester ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Ester Baiget (53 yo)

4.8yrs

Permanencia

€3,903,958

Compensación

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ester Baiget	President & CEO	4.8yrs	€3.90m	sin datos
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	sin datos
Anders Lund	Chief Operating Officer	less than a year	€1.03m	sin datos
Claus Fuglsang	Chief Scientific Officer	4.2yrs	sin datos	sin datos
Tobias Bjorklund	Head of Investor Relations	no data	sin datos	sin datos
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	sin datos	sin datos
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.6yrs	sin datos	sin datos
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.8yrs	€1.02m	sin datos
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.6yrs	sin datos	sin datos
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	sin datos	sin datos
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	sin datos	sin datos
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	sin datos	sin datos

3.6yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NZM2 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jesper Brandgaard	Vice Chair of the Board	less than a year	sin datos	sin datos
Cornelis de Jong	Independent Chairman	4.8yrs	€239.07k	0.0011% € 262.4k
Kim Stratton	Independent Director	7.8yrs	€173.33k	sin datos
Kasim Kutay	Director	7.8yrs	€107.73k	0.00023% € 55.9k
Heine Dalsgaard	Director	4.8yrs	€143.55k	0.00065% € 157.9k
Lise Kaae	Director	less than a year	sin datos	sin datos
Lena Holskov	Employee Representative Director	11.8yrs	€66.91k	sin datos
Anders Knudsen	Employee Representative Director	11.8yrs	€71.77k	sin datos
Sharon James	Independent Director	4.8yrs	€143.55k	sin datos
Preben Nielsen	Employee Representative Director	3.7yrs	€107.73k	0.000090% € 21.9k
Jens Obro	Employee Representative Director	3.7yrs	€71.77k	0.00012% € 29.2k
Morten Otto Sommer	Independent Director	2.7yrs	€137.51k	0.00022% € 53.5k

4.8yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NZM2 se considera experimentada (4.8 años de antigüedad promedio).

Novonesis Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Novonesis A/S Announces Board Changes

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Now 20% overvalued after recent price rise

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Upcoming Dividend of kr.5.25 Per Share

New 90-day high: €51.54

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

New 90-day low: €45.51